Introduction: Renal carcinoma, and in particular its most common variant, the clear cell subtype, is often diagnosed incidentally through abdominal imaging and frequently, the tumor is discovered at an early stage. However, 20% to 40% of patients undergoing nephrectomy for clinically localized renal cancer, even after accurate histological and clinical classification, will develop metastasis or recurrence, justifying the associated mortality rate. Therefore, even if renal carcinoma is not among the most frequent nor deadly cancers, a better prognostication is needed. Areas covered: Recently proteomics or other omics combinations have been applied to both cancer tissues, on the neoplasia itself and surrounding microenvironment, cultured cells, and biological fluids (so-called liquid biopsy) generating a list of prognostic molecular tools that will be reviewed in the present paper. Expert opinion: Although promising, none of the approaches listed above has been yet translated in clinics. This is likely due to the peculiar genetic and phenotypic heterogeneity of this cancer, which makes nearly each tumor different from all the others. Attempts to overcome this issue will be also revised. In particular, we will discuss how the application of omics-integrated approaches could provide the determinants of response to the different targeted drugs.

Raimondo, F., Pitto, M. (2020). Prognostic significance of proteomics and multi-omics studies in renal carcinoma. EXPERT REVIEW OF PROTEOMICS, 17(4), 323-334 [10.1080/14789450.2020.1772058].

Prognostic significance of proteomics and multi-omics studies in renal carcinoma

Raimondo, F;Pitto, M
2020

Abstract

Introduction: Renal carcinoma, and in particular its most common variant, the clear cell subtype, is often diagnosed incidentally through abdominal imaging and frequently, the tumor is discovered at an early stage. However, 20% to 40% of patients undergoing nephrectomy for clinically localized renal cancer, even after accurate histological and clinical classification, will develop metastasis or recurrence, justifying the associated mortality rate. Therefore, even if renal carcinoma is not among the most frequent nor deadly cancers, a better prognostication is needed. Areas covered: Recently proteomics or other omics combinations have been applied to both cancer tissues, on the neoplasia itself and surrounding microenvironment, cultured cells, and biological fluids (so-called liquid biopsy) generating a list of prognostic molecular tools that will be reviewed in the present paper. Expert opinion: Although promising, none of the approaches listed above has been yet translated in clinics. This is likely due to the peculiar genetic and phenotypic heterogeneity of this cancer, which makes nearly each tumor different from all the others. Attempts to overcome this issue will be also revised. In particular, we will discuss how the application of omics-integrated approaches could provide the determinants of response to the different targeted drugs.
Articolo in rivista - Review Essay
Cancer heterogeneity; liquid biopsy; multi-omics; proteomics; renal cell carcinoma;
English
323
334
12
Raimondo, F., Pitto, M. (2020). Prognostic significance of proteomics and multi-omics studies in renal carcinoma. EXPERT REVIEW OF PROTEOMICS, 17(4), 323-334 [10.1080/14789450.2020.1772058].
File in questo prodotto:
File Dimensione Formato  
RCC-prognosis-OMICs_revised_ERP2020.pdf

Accesso Aperto

Descrizione: Articolo completo
Tipologia di allegato: Author’s Accepted Manuscript, AAM (Post-print)
Dimensione 717.82 kB
Formato Adobe PDF
717.82 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/283658
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
Social impact